Literature DB >> 11585876

Phantom studies for estimation of defect size on cardiac (18)F SPECT and PET: implications for myocardial viability assessment.

I Matsunari1, T Yoneyama, S Kanayama, M Matsudaira, K Nakajima, J Taki, S G Nekolla, N Tonami, K Hisada.   

Abstract

UNLABELLED: SPECT with (18)F-FDG has emerged as an alternative to dedicated PET for the assessment of myocardial viability. However, whether FDG SPECT can reliably quantify the extent of viable and scarred myocardium is uncertain. The aim of this study was to investigate whether SPECT with an (18)F-labeled agent would provide information on defect size similar to that provided by dedicated PET.
METHODS: Imaging was performed using an elliptic cylinder chest phantom with simulated bone, lung, mediastinum, liver, and heart. (18)F was administered into the myocardium, mediastinum, right and left ventricular cavities, and liver. Plastic inserts (n = 11) ranging in size from 2% to 60% of the myocardium were used to simulate transmural myocardial infarctions. The chest phantom was imaged with a dedicated PET camera and with a double-head SPECT camera equipped with ultra-high-energy collimators. Both SPECT and PET data were analyzed using a semiquantitative polar map approach. Defects were quantified using various cutoff thresholds ranging from 30% to 80% of peak activity and were expressed as a percentage of the left ventricular myocardium. Defect size as measured by SPECT or PET was compared with true defect size.
RESULTS: The measured SPECT defect size was highly variable depending on the cutoff used, whereas PET defect size was relatively constant over the range of cutoffs tested. The mean absolute difference between measured and true defect sizes was minimal at a cutoff of 50% of peak activity for both SPECT (3.3% +/- 3.3%) and PET (2.7% +/- 2.5%). For this threshold, both SPECT and PET measurements showed an excellent correlation with true defect size (r = 0.98 for SPECT and 0.99 for PET). The correlation between SPECT and PET measurements was also excellent (r = 0.99; P < 0.01).
CONCLUSION: If an appropriate threshold is used to define a defect, SPECT with an (18)F-labeled agent can accurately measure defect size similarly to the manner of PET.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585876

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment.

Authors:  Ming Yu; Jody Bozek; Melanie Lamoy; Mikhail Kagan; Pedro Benites; David Onthank; Simon P Robinson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-04       Impact factor: 9.236

2.  Myocardial defect detection using PET-CT: phantom studies.

Authors:  Eugene S Mananga; Georges El Fakhri; Joshua Schaefferkoetter; Ali A Bonab; Jinsong Ouyang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

3.  Importance of Defect Detectability in Positron Emission Tomography Imaging of Abdominal Lesions.

Authors:  Shozo Yamashita; Kunihiko Yokoyama; Masahisa Onoguchi; Haruki Yamamoto; Tetsu Nakaichi; Shiro Tsuji; Kenichi Nakajima
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

4.  Comparison of 18F SPECT with PET in myocardial imaging: a realistic thorax-cardiac phantom study.

Authors:  Karin Knešaurek; Josef Machac
Journal:  BMC Nucl Med       Date:  2006-10-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.